Ville Salo

Ville Salo

Auto-generated profile, based on publicly available information

Ville Salo

University of Oulu

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVille Salo
Ville Salo
JMJuhani Määttä
Juhani Määttä
ESEeva Sliz
Eeva Sliz
EREne Reimann
Ene Reimann
RMReedik Mägi
Reedik Mägi
JKJohannes Kettunen
Johannes Kettunen
Given that lumbar disc herniation (LDH) is a prevalent spinal condition that causes significant individual suffering and societal costs, the genetic basis of LDH has received relatively little research. Our aim is to increase understanding of the genetic factors influencing LDH. We perform a genome-wide association analysis (GWAS) of LDH in the FinnGen project and in Estonian and UK biobanks, followed by a genome-wide meta-analysis to combine the results. In the meta-analysis, we identify 41 loci that have not been associated with LDH in prior studies on top of the 23 known risk loci. We detect LDH-associated loci in the vicinity of genes related to inflammation, disc-related structures, and synaptic transmission. Overall, our research contributes to a deeper understanding of the genetic factors behind LDH, potentially paving the way for the development of new therapeutics, prevention methods, and treatments for symptomatic LDH in the future.

6 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVille Salo
Ville Salo
JMJuhani Määttä
Juhani Määttä
JTJasmin Takala
Jasmin Takala
AHAnni Heikkilä
Anni Heikkilä
FGFinn Gen
Finn Gen
JKJohannes Kettunen
Johannes Kettunen
Lumbar spinal stenosis (LSS) affects over 100 million people globally, with an increasing incidence due to an ageing population. While LSS is known to be heritable, its genetic basis remains poorly understood. We conduct a genome-wide meta-analysis of LSS in 40,303 cases and 741,469 controls. We identify 73 previously unreported loci in addition to 15 known loci, and highlight spinal degeneration as a key pathogenic mechanism. In 12,784 surgically treated cases, we discover five loci specifically associated with severe disease. Age-of-onset analyses show that most variants influence risk after midlife, but some confer susceptibility as early as age 34. Mendelian randomization further demonstrates causal effects of higher body mass and fat-free mass on LSS risk. Overall, our findings expand knowledge of the genetic background of LSS and inform future translational research.

16 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
VSVille Salo
Ville Salo
JMJuhani Määttä
Juhani Määttä
ESEeva Sliz
Eeva Sliz
FGFinn Gen
Finn Gen
EREne Reimann
Ene Reimann
JKJohannes Kettunen
Johannes Kettunen
Introductory paragraph: Given that lumbar disc herniation (LDH) is a prevalent spinal condition that causes significant individual suffering and societal costs 1 , the genetic basis of LDH has received relatively little research. Our aim was to increase understanding of the genetic factors influencing LDH. We performed a genome-wide association analysis (GWAS) of LDH in the FinnGen project and in Estonian and UK biobanks, followed by a genome-wide meta-analysis to combine the results. In the meta-analysis, we identified 41 loci that have not been associated with LDH in prior studies on top of the 23 known risk loci. We detected LDH-associated loci in the vicinity of genes related to inflammation, disc-related structures, and synaptic transmission. Overall, our research contributes to a deeper understanding of the genetic factors behind LDH, potentially paving the way for the development of new therapeutics, prevention methods, and treatments for symptomatic LDH in the future.

13 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ABArgyro Bizaki-Vallaskangas
Argyro Bizaki-Vallaskangas
ESEeva Sliz
Eeva Sliz
TLTuuli Lankinen
Tuuli Lankinen
ESElmo Saarentaus
Elmo Saarentaus
VSVille Salo
Ville Salo
JKJohannes Kettunen
Johannes Kettunen
Purpose: Investigate the genetic components of sensorineural hearing loss (SNHL) by performing genome-wide meta-analyses using the data from FinnGen and Estonian Biobank. Methods: We studied genome-wide associations of SNHL in FinnGen and the Estonian Biobank in the general population and in sex- and age-of-onset stratified subgroups. The study-specific GWASs were combined through inverse variance-weighted genome-wide meta-analyses, encompassing a total of 531,059 individuals (Ncases=35,960). Age-stratified meta-analyses included 28,198 individuals diagnosed at the age of 55 years or after and 7,762 individuals diagnosed before the age of 55 years, with 495,099 controls. Sex-stratified meta-analyses included 313,501 females (Ncases=17,761) and 217,558 males (Ncases=18,199). Results: In the meta-analysis focusing on the general population, 22 SNHL-associated loci (±1 Mb window) were observed, seven of which were previously unreported. In the sex-stratified analysis, two previously unreported SNHL loci were observed in the female subgroup and one locus in the male subgroup. Additionally, in the age-stratified analysis, three previously unreported SNHL loci were observed in the subgroup of those that were diagnosed at the age of 55 years or after. In those diagnosed before the age of 55 years, one previously unreported locus was observed. Overall, 32 loci were associated with SNHL at p<5×10 −8 in at least one of the study groups. Of these, 14 loci have not been previously reported in association with SNHL. We also estimated if there were significant differences in the effect sizes of the lead variants at each locus between the analytical subgroups and observed differences for 14 variants. Conclusions: Previously unreported SNHL risk loci and differences in effect sizes found in this study provide additional insight into the genetic underpinnings of SNHL. Our results validate the role of mechano-transduction and genetic components affecting the structure of the inner ear in the background of SNHL. Our study contributes to our understanding of the genetic causes of SNHL and may open the door for further research into innovative therapies and preventative measures.

5 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJanne Pott
Janne Pott
AMAmy Mason
Amy Mason
VSVille Salo
Ville Salo
FIFinngen
Finngen
JKJohannes Kettunen
Johannes Kettunen
SBStephen Burgess
Stephen Burgess
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is well known for its causal effects on the lipid metabolism. A recent study identified an association between rs562556 within PCSK9 and breast cancer survival (BCS). It was suggested that PCSK9 inhibition might allow for early intervention strategies to prevent metastasizing breast cancer. Here, we attempt to replicate these findings by using genome-wide association study (GWAS) summary statistics in three 2-sample Mendelian Randomization (MR) approaches. Methods: We used publicly available GWAS summary statistics for PCSK9 and BCS from the Breast Cancer Association Consortium (N=99,217), and performed SNP association tests with BCS in the FinnGen study (N=4,648). First, we tested the MR-ratio using only the reported SNP rs562556, then tested the genetically proxied PCSK9 inhibition using the MR inverse variance weighted (IVW) approach, and finally adjusted for indirect effects of the lipid metabolism using multivariable MR (MVMR-IVW). Coronary artery disease and parental longevity were chosen as positive control outcomes. Results: We found no significant association between PCSK9 and BCS in neither the MR-ratio, MR-IVW nor MVMR-IVW approach. The positive controls were significant throughout. Conclusion: A significant positive effect of PCSK9 on BCS could only be reproduced when using the outcome data from the recent study, but not when using independent, larger GWASs. Impact: Potential reasons for the discrepant results are different genetic models, sample selection criteria, and the time-variability of Hazard Ratio estimates. They should be explored before considering PCSK9 a therapeutic target in BC patients.

12 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
VSVille Salo
Ville Salo
JKJohannes Kettunen
Johannes Kettunen
FGFinn Gen
Finn Gen
ETEstonian Biobank Research Team
Estonian Biobank Research Team
ESEeva Sliz
Eeva Sliz
Gout is the most common inflammatory joint disease caused by the crystallization of urate inside the joints. Patients with gout typically have abnormal blood lipid and sugar levels, which are associated with cardiovascular diseases. However, the relationship between gout and metabolic changes is unclear. Our goal was two-fold: to identify new gout risk factors using genome-wide association analysis and subsequently to investigate the effects of the identified risk alleles on metabolic measures in the bloodstream. We performed a genome-wide meta-analysis for gout in the FinnGen project, the Estonian Biobank, and the UK Biobank, encompassing a total of 992,583 individuals, including 17,972 gout cases. Given that gout is commonly recognized as a disease affecting the elderly, and males specifically, we further explored age- and sex-stratified genetic associations in FinnGen (10,885 cases and 366,392 controls). Finally, we determined the metabolomic consequences of the gout risk-increasing alleles using data from a large metabolomics GWAS. In the meta-analysis, we observed 32 genome-wide significant (P<5×10 −8 ) loci, one of which was novel. In the age- and sex-stratified analyses, we additionally identified one novel gout-associated locus in the male subgroup. The metabolomic findings suggested that the majority of the gout risk alleles primarily affected urate concentration in the bloodstream but not the concentrations of lipids and other metabolites. Therefore, it appears that the associations between gout and metabolic factors at the population level are likely explained by shared lifestyle risk factors. In conclusion, our study sheds new light on the genetic architecture of gout and adds to the growing body of evidence supporting the role of urate, but not other metabolic measures, including lipoprotein lipids and glucose, as a key risk factor for developing gout.